Tomoiki Aiba

Sendai, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Disease Kinetics and Practice Patterns in ≥4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer.

Disease Kinetics and Practice Patterns in ≥4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 14, 2026

Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer.

Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 15, 2025

Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report.

Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report.

Journal: Journal of medical case reports

Published: November 28, 2025

Corrigendum to 'Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)' [Journal of Thoracic Oncology Vol. 20 No. 7 (2025) 912-927].

Corrigendum to 'Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)' [Journal of Thoracic Oncology Vol. 20 No. 7 (2025) 912-927].

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 07, 2025

Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio.

Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio.

Journal: Translational lung cancer research

Published: September 25, 2025

A case of lower respiratory tract infection caused by Pandoraea sputorum in a human T-lymphotropic virus type 1 carrier.

A case of lower respiratory tract infection caused by Pandoraea sputorum in a human T-lymphotropic virus type 1 carrier.

Journal: IDCases

Published: June 16, 2025

Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer.

Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer.

Journal: Translational lung cancer research

Published: May 31, 2025

Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON).

Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON).

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: January 09, 2025

Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome.

Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome.

Journal: Cancer reports (Hoboken, N.J.)

Published: March 02, 2024

Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.

Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.

Journal: Cancer reports (Hoboken, N.J.)

Published: August 02, 2023

Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.

Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.

Journal: Thoracic cancer

Published: June 08, 2023

Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01).

Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01).

Journal: Cancer medicine

Published: October 04, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026